MESOBLAST LTDMESOEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
MESO Q3 FY2023 Key Financial Metrics
Revenue
$1.9M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-18.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-959.3%
YoY Growth
-3.6%
EPS
$-0.03
MESOBLAST LTD Q3 FY2023 Financial Summary
MESOBLAST LTD reported revenue of $1.9M (down 3.6% YoY) for Q3 FY2023, with a net profit of $-18.6M (up 12.7% YoY) (-959.3% margin).
Key Financial Metrics
| Total Revenue | $1.9M |
|---|---|
| Net Profit | $-18.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2023 |
MESOBLAST LTD Quarterly Revenue & Net Profit History
MESOBLAST LTD results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2023 | $1.9M | -3.6% | $-18.6M | -959.3% |
| Q2 FY2023 | $2.1M | -10.4% | $-24.5M | -1147.4% |
| Q1 FY2023 | $1.5M | -58.2% | $-16.9M | -1123.4% |
| Q3 FY2022 | $2.0M | +5.0% | $-21.3M | -1059.3% |
| Q2 FY2022 | $2.4M | — | $-25.9M | -1088.8% |
| Q1 FY2022 | $3.6M | — | $-22.6M | -630.1% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | $2.4M | $2.0M | $1.5M | $2.1M | $1.9M |
| YoY Growth | N/A | N/A | 5.0% | -58.2% | -10.4% | -3.6% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Assets | $721.8M | $704.4M | $681.7M | $684.5M | $668.1M | $650.4M |
| Liabilities | $162.1M | $168.9M | $164.6M | $161.7M | $168.1M | $168.3M |
| Equity | $559.7M | $535.5M | $517.1M | $522.8M | $500.0M | $482.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Operating CF | $-18.2M | $-18.2M | $-15.5M | $-14.3M | $-16.5M | $-16.3M |